CCN2 and gastric cancer: While considering both DUB1 and CTGF expression, the prognosis was poor in HighCTGF+DUB1 compared with LowCTGF+DUB1 group in gastric cancer patients (Median survival: 28.8 month vs 89.4 month; P < 0.0001) (Supplementary Fig. 2F-2G).